Veraxa Biotech AGNASDAQ: VRXA

VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

· Issued by Veraxa Biotech AG

Summary by 6ix AI

VERAXA Biotech, which develops antibody-based cancer therapies, said on August 24, 2026 that its VXA-222 bispecific antibody-drug conjugate (an antibody that binds two targets and carries a drug) has moved beyond the initial discovery phase after it completed the antibody-discovery step with OmniAb.

Key details

  • VERAXA is now responsible for engineering the final VXA-222 therapeutic candidate using antibody binders generated through the OmniAb collaboration.
  • The company has advanced its lead BiTAC-TCE, a T-cell engager (a drug designed to direct immune T cells to cancer cells), toward IND/CTA-enabling activities, the work that supports applications to start clinical trials. This followed cell-line development work and regulatory feedback from Germany's Paul-Ehrlich-Institute.
  • VERAXA says its proprietary BiTAC platform uses a dual-targeting, "AND-gated" design meant to activate therapeutic effects preferentially at tumor sites.
  • The company reported more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, plus additional pending patent applications.

What’s still pending

  • The final VXA-222 therapeutic candidate has not yet been engineered.
  • The lead BiTAC-TCE has advanced toward, but not completed, the work needed before clinical trial applications.

6ix AI wrote this summary from the release below and checked it against the release.

Featured Image

Austin, Texas, United States, August 24th, 2026, NewsDirect

  • VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates ("ADCs") and T-cell engagers ("TCEs").
  • Its proprietary BiTAC platform uses a dual-targeting, "AND-gated" architecture designed to activate therapeutic effects preferentially at tumor sites.
  • The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany's Paul-Ehrlich-Institute.
  • VERAXA's VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb.
  • The company reported more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, alongside additional pending applications.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is advancing its oncology pipeline with a strategy centered on changing how antibody-based therapies recognize and attack cancer cells. The biotechnology company is developing bispecific antibody-drug conjugates, T-cell engagers and other engineered antibody formats, with its proprietary BiTAC technology providing the distinctive element of its approach.

The latest pipeline development involves VXA-222, a bispecific antibody-drug conjugate that has moved beyond the initial discovery phase following the completion of VERAXA's collaboration with OmniAb. VERAXA is now responsible for engineering the final therapeutic candidate using antibody binders generated through the collaboration, followed by...

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to VRXA are available in the company's newsroom at https://ibn.fm/VRXA

Contact
IBNwww.InvestorBrandNetwork.com[email protected]

Veraxa Biotech AG on 6ix

Earlier from Veraxa Biotech

Later from Veraxa Biotech

All Veraxa Biotech news releases